

Maria Kamusheva

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4492525/publications.pdf>

Version: 2024-02-01

47
papers

333
citations

932766

10
h-index

940134

16
g-index

48
all docs

48
docs citations

48
times ranked

456
citing authors

#	ARTICLE	IF	CITATIONS
1	The European challenges of funding orphan medicinal products. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 184.	1.2	34
2	Proposal for a regulation on health technology assessment in Europe – opinions of policy makers, payers and academics from the field of HTA. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 251-261.	0.7	31
3	Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2018, 9, 1070.	1.6	30
4	Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines. <i>Frontiers in Pharmacology</i> , 2018, 9, 794.	1.6	22
5	Life expectancy and survival analysis of patients with diabetes compared to the non diabetic population in Bulgaria. <i>PLoS ONE</i> , 2020, 15, e0232815.	1.1	21
6	Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. <i>SAGE Open Medicine</i> , 2017, 5, 205031211769040.	0.7	18
7	<p>The Potential Role of the Pharmacist in Supporting Patients with Depression – A Literature-Based Point of View</p>. <i>Integrated Pharmacy Research & Practice</i> , 2020, Volume 9, 49-63.	0.9	15
8	Influence of COVID-19 on Health-Related Quality of Life and the Perception of Being Vaccinated to Prevent COVID-19: An Approach for Community Pharmacists from Romania and Bulgaria. <i>Journal of Clinical Medicine</i> , 2021, 10, 864.	1.0	14
9	Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. <i>Journal of Medical Economics</i> , 2017, 20, 503-509.	1.0	13
10	Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries. <i>Frontiers in Pharmacology</i> , 2018, 9, 795.	1.6	13
11	New Epidemiological, Clinical and Economic Data for Patients With Acromegaly in Bulgaria. <i>Frontiers in Public Health</i> , 2020, 8, 147.	1.3	12
12	A Systematic Review of Collective Evidences Investigating the Effect of Diabetes Monitoring Systems and Their Application in Health Care. <i>Frontiers in Endocrinology</i> , 2021, 12, 636959.	1.5	12
13	A Cross-Country Comparison of Reimbursed Orphan Medicines in Bulgaria, Greece and Romania. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4186-4192.	0.5	9
14	Pharmacist's Perspectives on Administering a COVID-19 Vaccine in Community Pharmacies in Four Balkan Countries. <i>Frontiers in Public Health</i> , 2021, 9, 766146.	1.3	8
15	Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 905-913.	0.6	7
16	Evaluation of the economic and social burden of chronic obstructive pulmonary disease (COPD). <i>Biotechnology and Biotechnological Equipment</i> , 2017, , 1-7.	0.5	6
17	Chronic obstructive pulmonary disease exacerbations and progression in relation to ambient air pollutants exposure. <i>Journal of Thoracic Disease</i> , 2019, 11, 2490-2497.	0.6	6
18	Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 733-742.	0.7	6

#	ARTICLE	IF	CITATIONS
19	Orphan medicinal productsâ€™ access to the Bulgarian pharmaceutical market â€“ challenges and obstacles. Expert Opinion on Orphan Drugs, 2018, 6, 95-104.	0.5	5
20	Costs and outcomes for individuals with psychosis prior to hospital admission and following discharge in Bulgaria. Social Psychiatry and Psychiatric Epidemiology, 2019, 54, 1353-1362.	1.6	5
21	Do Advanced Therapies Have a Future in the Low- and Middle-Income Countries - The Case of Bulgaria, Romania, and Poland. Frontiers in Public Health, 2021, 9, 729847.	1.3	5
22	Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe. Applied Health Economics and Health Policy, 2021, 19, 915-927.	1.0	5
23	An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. Frontiers in Public Health, 2018, 6, 61.	1.3	4
24	Budget Impact Analysis of Chronic Myeloid Leukemia Treatment in Bulgaria. Biotechnology and Biotechnological Equipment, 2013, 27, 3595-3598.	0.5	3
25	Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting. Biotechnology and Biotechnological Equipment, 2014, 28, 366-371.	0.5	3
26	The Health Related Quality of Life for Kidney Transplant Patients in Bulgariaâ€™A Pilot Study. Biotechnology and Biotechnological Equipment, 2012, 26, 3062-3065.	0.5	2
27	Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system. Biotechnology and Biotechnological Equipment, 2019, 33, 1-11.	0.5	2
28	Improved quality of diabetes control reduces complication costs in Bulgaria. Biotechnology and Biotechnological Equipment, 2019, 33, 814-820.	0.5	2
29	Pilot Study on the Cost of Some Oncohematology Diseases in Bulgaria. Frontiers in Public Health, 2019, 7, 70.	1.3	2
30	Economic and pharmaco-economic analysis of acromegaly treatment: a systematic review. Biotechnology and Biotechnological Equipment, 2019, 33, 1560-1571.	0.5	2
31	Analysis of patientsâ€™ access to reimbursed biotechnological medicines for multiple sclerosis in Bulgaria and Greece. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 241-246.	0.7	2
32	Screening and diagnosis of chronic HCV infection in Bulgaria: A review of the current practice. Biomedical Research (Aligarh, India), 2018, 29, .	0.1	2
33	A HEALTH-RELATED QUALITY OF LIFE AND PHARMACOTHERAPY COSTS STUDY FOR PATIENTS WITH CYSTIC FIBROSIS, GAUCHER DISEASE AND CHRONIC MYELOID LEUKEMIA IN BULGARIA. Biotechnology and Biotechnological Equipment, 2013, 27, 3896-3900.	0.5	2
34	Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA. International Journal of Diabetes in Developing Countries, 2018, 38, 520-521.	0.3	1
35	Cost-effectiveness analysis of current treatment of individuals with acute exacerbation of schizophrenia in Bulgaria. Biotechnology and Biotechnological Equipment, 2019, 33, 204-213.	0.5	1
36	Clinical and economic assessment of nusinersen: the Bulgarian perspective. Expert Opinion on Orphan Drugs, 2020, 8, 403-415.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Cardiovascular co-morbidity in patients with COPD in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2020, 34, 918-924.	0.5	1
38	Social and economic burden of breast cancer in the North East region of Bulgaria. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 1-7.	0.7	1
39	Pharmaco-therapeutic Patterns and Patients' Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 695181.	1.6	1
40	Rare disease patients' needs: an up-to-date analysis and future directions. <i>Pharmacia</i> , 2021, 68, 763-770.	0.4	1
41	A one-way, static Markov model estimating the social and economic burden of chronic obstructive pulmonary disease in Bulgaria for patients who smoke or don't. <i>Biomedical Research (Aligarh, India)</i> , 2018, 29, .	0.1	1
42	Polycystic ovary syndrome impact on women's quality of life: pilot study. <i>Biomedical Research (Aligarh, India)</i> , 2018, 29, .	0.1	1
43	Screening for depression among chronically ill patients in community pharmacy settings: a pilot study in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1393-1400.	0.5	1
44	Incretins and SGLT-2i Therapy of Type 2 Diabetes – Real Life Study of Their Therapeutic and Economic Effects. <i>Frontiers in Pharmacology</i> , 2019, 10, 364.	1.6	0
45	Review of medicine utilization for Parkinson's disease management: the Bulgarian perspective. <i>Journal of Public Health Research</i> , 2021, , .	0.5	0
46	Volume and trends of adalimumab and pembrolizumab reimbursed market: the Bulgarian perspective. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1778-1791.	0.5	0
47	Pharmacoeconomic analysis of pertussis booster dose in adolescents in Bulgaria. <i>Biotechnology and Biotechnological Equipment</i> , 2021, 35, 1977-1989.	0.5	0